Dr. Peter Haug brings over 20 years of senior management experience in the chemical and pharmaceutical industry to co-found and develop start-ups in Chemistry, Cleantech, Biotech and Pharma.
The Founding Angel model combines substantial industry know-how with entrepreneurial commitment. Peter Haug joins early-stage ventures as an active co-founder, contributing strategy, networks, business development and leadership — not just capital.
A Founding Angel is not a passive investor or a pure mentor. He becomes a true co-founder: taking responsibility for specific functional areas, opening doors to industrial partners, customers and investors, and sharing the risk of the entrepreneurial journey.
This model is especially powerful in sectors that require deep technical and regulatory knowledge — Chemistry, Cleantech, Biotech and Pharma — where industry experience is a rare and decisive competitive advantage.
Senior management in CDMO, holding and specialty chemicals groups
Co-founder in 5 ventures across chemistry, cleantech, biotech & pharma
Connecting academic inventions with industrial markets and capital
Partnerships, licensing, clinical validation and market entry strategy
Five companies co-founded and developed across Chemistry, Cleantech, Biotech and Pharma — from initial concept through Series A funding, award-winning product launches and strategic exits.
Rapid molecular diagnostics for life-threatening infectious diseases. Next-generation sequencing of pathogen DNA from blood — results within hours instead of days.
Learn more
Epigenetics-based cervical cancer diagnostics. The GynTect® test detects aberrant DNA methylation patterns to identify cervical cancer with high specificity.
Learn moreInnovative process to convert waste cooking oil and animal fats into high-quality bio-jet fuel and other fuels — without transesterification and with higher yields.
Learn more
3D cell culture scaffolds for pharmaceutical research and drug development. Winner of the CyberForum Startup Award 2014.
Learn moreInnovative Raman micro-spectroscopy technology for rapid, non-destructive analysis of surfaces and materials. Applications in quality control and research.
Learn moreDeep sectoral knowledge built over two decades in senior management positions — now deployed for start-up success.
Recent coverage from across the portfolio companies and thought leadership articles.
noscendo GmbH successfully closed a Series B financing round to advance its next-generation sequencing platform for rapid pathogen identification in critically ill patients.
noscendo press releaseoncgnostics GmbH signed a licensing agreement with a Chinese diagnostics company for the GynTect® cervical cancer test — opening access to one of the world's largest markets.
oncgnostics / 360DxThe AWS (Austria Wirtschaftsservice) selected noscendo for its prestigious start-up grant, supporting further development of the DISQVER® diagnostic system for sepsis.
AWS / noscendoTwo decades of senior management in the chemical and pharmaceutical industry form the foundation of the Founding Angel approach.
Strategic and operational leadership across multiple production sites for a leading European contract development and manufacturing organisation.
Group-level strategy, M&A, and new business development across a diversified specialty chemicals holding company.